{"doi":"10.37766/inplasy2024.5.0036","title":"Body Size and Body Composition in Relation to the PI3K/AKT/MTOR Pathway Informing Cancer Risk and Outcomes: A Systematic Review","abstract":"eview question / Objective The main objective is to systematically review the associations between body fatness and body composition with the PI3K/AKT/MTOR pathway in cancer populations and identify research gaps for future studies.Research questions: 1) Do molecular markers of the PI3K/AKT/MTOR pathway in tumor, adipose, or muscle tissue correlate with body size and/or body composition?2) What is the current evidence of how these molecular markers, together with body fatness and/or body composition, predict cancer risk and clinical outcomes (recurrence, metastasis, death)?3) Which molecular markers directly or indirectly involved in the PI3K/AKT/MTOR pathway in tumor, adipose, or muscle tissue have been investigated in relation to body fatness and/or body composition in human populations with cancer or with high risk of cancer?Rationale Overactivation of the mechanistic target of rapamycin (MTOR) pathway is associated with tumor growth, but the extent to which body size and fatness are associated with mTOR pathway activities in cancer is yet to be summarized.The MTOR pathway is activated by energy influx, amino acids, and insulin-like growth factors (IGFs), and activation of the pathway promotes several cancer hallmarks, such as cell proliferation and angiogenesis.The pathway activation entails a cascade of protein phosphorylation, a posttranslational process.Phosphorylated MTOR and its upstream, including PI3K and AKT, and downstream proteins, such as P70S6 Kinase (P70S6K), are highly expressed in solid tumors related to obesity.Obesity is often characterized by body size measured as body mass index (BMI), waist c i rc u m f e re n c e , a n d o t h e r a n t h ro p o m e t r y measurements.Recent advancements utilize clinical images, including DXA, CT, and MRI scans for body composition measurements.The individual components of body composition, such INPLASY 1","journal":null,"year":2024,"id":483324,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9642,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1324505,"name":"Mahenge Cuthbert","orcid":null,"position":1,"is_corresponding":false},{"id":225432,"name":"Faiza Kalam","orcid":"0000-0003-4326-4009","position":2,"is_corresponding":false},{"id":959691,"name":"Anita Adib","orcid":"0009-0006-8640-5544","position":3,"is_corresponding":false},{"id":1324506,"name":"Stephanie Schulte","orcid":null,"position":4,"is_corresponding":false},{"id":420899,"name":"Ting‐Yuan David Cheng","orcid":"0000-0002-4105-828X","position":5,"is_corresponding":false},{"id":908876,"name":"Rand T. Akasheh","orcid":"0000-0002-0018-0342","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:07:22.248464Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}